RT Journal Article
SR Electronic
T1 DNA Adduct Assessment During Antihormonal Treatment of Perianal Gland Tumors With Tamoxifen in Male Dogs
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 731
OP 735
DO 10.21873/invivo.11532
VO 33
IS 3
A1 ADAM BRODZKI
A1 MARCIN R. TATARA
A1 PIOTR BRODZKI
A1 IRENEUSZ BALICKI
YR 2019
UL http://iv.iiarjournals.org/content/33/3/731.abstract
AB Background/Aim: Determination of DNA adduct count was performed in mononuclear cells during antihormonal treatment of perianal gland tumors. Materials and Methods: Eight- to fifteen-year-old dogs with carcinoma (CAR Group; N=5), epithelioma (EPI Group; N=16) or adenoma (ADE Group; N=24) were used. The control group suffered from perineal hernia or rectal diverticulum (CTR Group; N=25). Blood was collected at baseline, and at one and six months after the beginning of the anti-hormonal treatment with tamoxifen (1 mg/kg of body weight). DNA adduct count was determined using autoradiography. Results: At baseline, DNA adduct count reached the highest value in the CTR Group, and the lowest in the EPI Group (p<0.05). Six-month-long therapy with tamoxifen resulted in a significant increase in the DNA adduct count by 78.7%, 221.5% and 198.3% in the ADE, EPI and CAR groups, respectively (p<0.05). Conclusion: Increased DNA adduct formation after long-term administration of tamoxifen shows its genotoxicity.